Project 2: Enhancing Efficacy of Gemcitabine Nanoparticles in Pancreatic PDX Models

项目总结/摘要：完整项目2 胰腺癌（PCa）是一种对所有受影响的人都具有毁灭性的疾病。目前，PCa是第三大原因， 在美国，癌症相关的死亡率为7.2%，令人沮丧。虽然PCa尚未 记录为癌症健康差距，数据相当惊人，例如，黑人经历了更高的 与他们的白人相比，此外，黑人男性和女性的总体生存率最低， PCa的比率。有趣的是，虽然许多癌症的发病率在5年内有所下降， 在2008-2012年期间，预计PCa的发病率和死亡人数将显著增加 在全国黑人中，进一步指出PCa是癌症健康差异。此外，虽然我们有 前列腺癌、乳腺癌和结肠/直肠癌的总生存率有显著改善， 到2030年成为癌症死亡的第二大原因。目前，还没有PCa的筛查试验， 早期诊断是困难的，因为前列腺癌经常在没有任何症状的情况下发展，并且适应症是非特异性的。 因此，需要新的抗癌药物递送，其将增强现有药物的功效，例如， 吉西他滨用于改善PCa患者结局。这项合作研究提出了调查关键 PCa治疗的障碍，也为代表性不足的患者定义了更个性化的治疗方法。 少数PCa患者。我们将识别分子特征，帮助区分分子签名 黑人和拉丁美洲人之间的胰腺肿瘤之间的差异，这将允许一个更个性化的方法， 目标是前列腺癌我们计划设计和开发硬脂酰连接的吉西他滨与表面修饰的抗EGFR 抗体纳米颗粒（GemEnps）;评估GemEnps作为潜在的替代化疗药物， 基于PCa原位PDX胰腺动物模型治疗的异同 对黑人、拉丁美洲人和白人的胰腺癌基因组进行测序，并翻译DNA知识 变更临床工具，以更好地管理患有PCa的黑人和拉丁美洲人。

PROJECT SUMMARY/ABSTRACT: FULL PROJECT 2 Pancreatic Cancer (PCa) is a devastating disease for all affected. Presently, PCa is the 3rd leading cause of cancer-related death in the U.S. The five-year overall survival rate is a dismal 7.2%. While PCa has not be recorded as a cancer health disparity, the data is quite alarming, for example, Blacks experience a higher prevalence of compared to their Whites. Moreover, Black men and women have the lowest overall survival rates of PCa. Interestingly, while many cancers have demonstrated a reduction in incidence over a 5-year period (2008-2012), the incidence and number of deaths from PCa are projected to significantly increase among Blacks nationwide, further fingering PCa as a cancer health disparity. Additionally, although we have seen significant improvements in overall survival for prostate, breast, and colon/rectal cancer, PCa is projected to be the second leading cause of cancer deaths by 2030. Presently, there are no screening tests for PCa and early diagnosis is difficult because PCa often develops without any symptoms and indications are nonspecific. Thus there is a need, novel anticancer drug delivery that will enhance the efficacy of existing drugs, such as Gemcitabine for use to improve PCa patient outcomes. This collaborative study proposes to investigate critical barriers to PCa therapeutics and also define a more personalized therapeutic approach for underrepresented minority PCa patients. We will identify molecular charateristics that help differentiate molecular signature between pancreatic tumors among Blacks and Latinos which will allow for a more personalized approach to targeting PCa. We plan to design and develop stearoyl-linked-Gemcitabine with surface modified anti-EGFR antibody nanoparticles (GemEnps); evaluate GemEnps as a potential alternative chemotherapeutic agent in the treatment of PCa orthotopic PDX pancreatic animal models based on the similarities and differences in sequencing of pancreatic cancer genomes of Blacks, Latinos and Whites and translate knowledge of DNA changes to clinical tools for better management of Black and Latino with PCa.